Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy

被引:0
|
作者
Waede, Mie [1 ,2 ,3 ]
Voss, Lasse F. [4 ]
Kingo, Christina [1 ,2 ,3 ]
Moeller, Jesper B. [3 ,5 ]
Elkjaer, Maria L. [1 ,2 ,3 ,6 ]
Illes, Zsolt [1 ,2 ,3 ,7 ]
机构
[1] Odense Univ Hosp, Dept Neurol, Odense, Denmark
[2] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[3] Univ Southern Denmark, Dept Mol Med, Odense, Denmark
[4] Tech Univ Denmark, Dept Hlth Technol, Sect Expt & Translat Immunol, Lyngby, Denmark
[5] Univ Southern Denmark, Danish Inst Adv Study, Odense, Denmark
[6] Univ Hamburg, Inst Computat Syst Biol, Hamburg, Germany
[7] Univ Southern Denmark, BRIDGE Brain Res Interdisciplinary Guided Excellen, Odense, Denmark
来源
关键词
NATURAL-KILLER-CELLS; T-CELLS; CHEMOKINE RECEPTORS; NK CELLS; CEREBROSPINAL-FLUID; ACTIVATION; EXPRESSION; RITUXIMAB; CD38; INFLAMMATION;
D O I
10.1002/acn3.52182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Anti-CD20 therapy is a highly effective treatment for multiple scle-rosis (MS). In this study, we investigated MS-related changes in peripheralblood mononuclear cell (PBMC) subsets compared to healthy controls and lon-gitudinal changes related to the treatment.Methods: Multicolor spectral flowcytometry analysis was performed on 78 samples to characterize disease- andtreatment-related PBMC clusters. Blood samples from MS patients were col-lected at baseline and up to 8 months post-treatment, with three collectionpoints after treatment initiation. Unsupervised clustering tools and manual gat-ing were applied to identify subclusters of interest and quantify changes. Results: B cells were depleted from the periphery after anti-CD20 treatment asexpected, and we observed an isolated acute, transitory drop in the proportionof natural killer (NK) and NKT cells among the main populations of PBMC(P=0.03,P=0.004). Major affected PBMC subpopulations were cytotoxicimmune cells (NK, NKT, and CD8(+)T cells), and we observed a higher propor-tion of cytotoxic cells with reduced brain-homing ability and a higher regula-tory function as a long-term anti-CD20-related effect. Additionally, anti-CD20therapy altered distributions of memory CD8(+)T cells and reduced exhaustionmarkers in both CD4(+)and CD8(+)T cells.Interpretation: The findings of thisstudy elucidate phenotypic clusters of NK and CD8(+)T cells, which have previ-ously been underexplored in the context of anti-CD20 therapy. Phenotypicmodifications towards a more regulatory and controlled phenotype suggest thatthese subpopulations may play a critical and previously unrecognized role inmediating the therapeutic efficacy of anti-CD20 treatments.
引用
收藏
页码:2657 / 2672
页数:16
相关论文
共 50 条
  • [31] Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
    Alvarez, Enrique
    Longbrake, Erin E.
    Rammohan, Kottil W.
    Stankiewicz, James
    Hersh, Carrie M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [32] CD11c+ B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy
    El Mahdaoui, Sahla
    Hansen, Marie Mathilde
    von Essen, Marina Rode
    Hvalkof, Victoria Hyslop
    Hansen, Rikke Holm
    Mahler, Mie Reith
    Jennum, Poul
    Sellebjerg, Finn
    Christensen, Jeppe Romme
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (04): : 926 - 937
  • [33] Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients
    Garcia-Carrasco, M.
    Mendoza-Pinto, C.
    Sandoval-Cruz, M.
    Soto-Vega, E.
    Beltran-Castillo, A.
    Jimenez-Hernandez, M.
    Graillet, D.
    Gonzalez, L.
    Rojas-Rodriguez, J.
    Pineda-Almazana, A.
    Zamudio-Huerta, L.
    Lopez-Colombo, A.
    LUPUS, 2010, 19 (02) : 213 - 219
  • [34] Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis
    Sabatino, Joseph J., Jr.
    Wilson, Michael R.
    Calabresi, Peter A.
    Hauser, Stephen L.
    Schneck, Jonathan P.
    Zamvil, Scott S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (51) : 25800 - 25807
  • [35] Anti-CD20 Therapy Depletes Activated Myelin-Specific CD8+ T Cells in Multiple Sclerosis
    Sabatino, Joseph, Jr.
    Wilson, Michael
    Calabresi, Peter
    Hauser, Stephen
    Schneck, Jonathan
    Zamvil, Scott
    ANNALS OF NEUROLOGY, 2019, 86 : S271 - S271
  • [36] Should anti-CD20 be used as an immune reconstitution therapy?
    Smets, Ide
    Wokke, Beatrijs
    Smolders, Joost
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (02) : 308 - 310
  • [37] Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
    Apostolidis, Sokratis A.
    Kakara, Mihir
    Painter, Mark M.
    Goel, Rishi R.
    Mathew, Divij
    Lenzi, Kerry
    Rezk, Ayman
    Patterson, Kristina R.
    Espinoza, Diego A.
    Kadri, Jessy C.
    Markowitz, Daniel M.
    Markowitz, Clyde E.
    Mexhitaj, Ina
    Jacobs, Dina
    Babb, Allison
    Betts, Michael R.
    Prak, Eline T. Luning
    Weiskopf, Daniela
    Grifoni, Alba
    Lundgreen, Kendall A.
    Gouma, Sigrid
    Sette, Alessandro
    Bates, Paul
    Hensley, Scott E.
    Greenplate, Allison R.
    Wherry, E. John
    Li, Rui
    Bar-Or, Amit
    NATURE MEDICINE, 2021, 27 (11) : 1990 - +
  • [38] Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
    Sokratis A. Apostolidis
    Mihir Kakara
    Mark M. Painter
    Rishi R. Goel
    Divij Mathew
    Kerry Lenzi
    Ayman Rezk
    Kristina R. Patterson
    Diego A. Espinoza
    Jessy C. Kadri
    Daniel M. Markowitz
    Clyde E. Markowitz
    Ina Mexhitaj
    Dina Jacobs
    Allison Babb
    Michael R. Betts
    Eline T. Luning Prak
    Daniela Weiskopf
    Alba Grifoni
    Kendall A. Lundgreen
    Sigrid Gouma
    Alessandro Sette
    Paul Bates
    Scott E. Hensley
    Allison R. Greenplate
    E. John Wherry
    Rui Li
    Amit Bar-Or
    Nature Medicine, 2021, 27 : 1990 - 2001
  • [39] BLOCKING B-CELLS (ANTI-CD20/ANTI-CD20)
    Isenberg, David A.
    RHEUMATOLOGY, 2015, 54 : 1 - 1
  • [40] A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery
    Sutter, Jennifer A.
    Kwan-Morley, Jennifer
    Dunham, Jon
    Du, Yang-Zhu
    Kamoun, Malek
    Albert, Daniel
    Eisenberg, Robert A.
    Prak, Eline T. Luning
    CLINICAL IMMUNOLOGY, 2008, 126 (03) : 282 - 290